The stock of ResMed Inc. (NYSE:RMD) is a huge mover today! About 280,494 shares traded hands. ResMed Inc. (NYSE:RMD) has risen 11.28% since March 3, 2016 and is uptrending. It has outperformed by 2.94% the S&P500.
The move comes after 9 months positive chart setup for the $9.07B company. It was reported on Oct, 6 by Barchart.com. We have $80.75 PT which if reached, will make NYSE:RMD worth $2.27B more.
Analysts await ResMed Inc. (NYSE:RMD) to report earnings on October, 27. They expect $0.63 EPS, up 8.62% or $0.05 from last year’s $0.58 per share. RMD’s profit will be $88.45 million for 25.63 P/E if the $0.63 EPS becomes a reality. After $0.74 actual EPS reported by ResMed Inc. for the previous quarter, Wall Street now forecasts -14.86% negative EPS growth.
ResMed Inc. (NYSE:RMD) Ratings Coverage
Out of 11 analysts covering ResMed Inc (NYSE:RMD), 4 rate it a “Buy”, 3 “Sell”, while 4 “Hold”. This means 36% are positive. ResMed Inc has been the topic of 17 analyst reports since August 3, 2015 according to StockzIntelligence Inc. JP Morgan initiated it with “Neutral” rating and $64 target price in Tuesday, October 4 report. The firm has “Underweight” rating given on Thursday, April 7 by Barclays Capital. The company was downgraded on Thursday, December 17 by Needham. The firm earned “Neutral” rating on Thursday, April 28 by Macquarie Research. The firm has “Neutral” rating given on Monday, September 19 by JP Morgan. The firm has “Buy” rating given on Friday, September 25 by Goldman Sachs. The rating was upgraded by Credit Suisse to “Outperform” on Friday, January 22. The rating was downgraded by Barclays Capital on Tuesday, January 19 to “Underweight”. The firm has “Buy” rating given on Thursday, September 29 by Bank of America. The stock has “Underperform” rating given by Jefferies on Tuesday, August 23.
According to Zacks Investment Research, “ResMed Inc. is a leading designer, manufacturer and distributor of medical equipment for treating and diagnosing sleep disordered breathing. Sleep disordered breathing includes sleep apnea and related respiratory conditions. The company sells a comprehensive range of diagnostic and treatment devices in countries through a combination of wholly owned subsidiaries and independent distributors.”
Insitutional Activity: The institutional sentiment decreased to 1.44 in 2016 Q2. Its down 0.01, from 1.45 in 2016Q1. The ratio fall, as 42 funds sold all ResMed Inc. shares owned while 87 reduced positions. 36 funds bought stakes while 150 increased positions. They now own 83.87 million shares or 2.40% more from 81.90 million shares in 2016Q1.
Strs Ohio accumulated 16,090 shares or 0% of the stock. Geneva Advsr Limited Liability Company, a Illinois-based fund reported 5,050 shares. Jane Street Group Inc Limited Liability Company has invested 0% of its portfolio in ResMed Inc. (NYSE:RMD). Weaver C Barksdale Assoc reported 140 shares or 0.02% of all its holdings. Cibc Ww Mkts Inc accumulated 7,873 shares or 0% of the stock. Gotham Asset Mngmt Ltd Co has 262,958 shares for 0.2% of their US portfolio. Shinko Asset has 1,733 shares for 0% of their US portfolio. Ww Asset Mngmt accumulated 0.02% or 7,346 shares. State Board Of Administration Of Florida Retirement Systems last reported 0.05% of its portfolio in the stock. West Coast Fincl Limited Co holds 1.73% of its portfolio in ResMed Inc. (NYSE:RMD) for 75,749 shares. Dynamic Advsrs Solutions Ltd Liability Corporation last reported 23,975 shares in the company. Martingale Asset Mngmt Limited Partnership owns 119,659 shares or 0.13% of their US portfolio. Cape Cod Five Cents National Bank & Trust owns 43,935 shares or 0.51% of their US portfolio. Meiji Yasuda Asset Mngmt Communication Limited holds 0.04% or 4,447 shares in its portfolio. Signaturefd Ltd Liability Co has 0% invested in the company for 474 shares.
Insider Transactions: Since April 15, 2016, the stock had 0 insider purchases, and 24 selling transactions for $21.94 million net activity. $1.27 million worth of ResMed Inc. (NYSE:RMD) shares were sold by FARRELL PETER C. On Friday, April 15 the insider Farrell Michael J. sold $354,557. Another trade for 6,000 shares valued at $336,120 was sold by PENDARVIS DAVID. The insider Sandercock Brett sold 35,000 shares worth $2.47 million. Hollingshead James also sold $178,994 worth of ResMed Inc. (NYSE:RMD) on Thursday, July 14. WAREHAM JOHN P sold $1.71 million worth of stock or 24,390 shares. SULPIZIO RICHARD had sold 36,000 shares worth $2.53 million on Wednesday, August 10.
More recent ResMed Inc. (NYSE:RMD) news were published by: Forbes.com which released: “ResMed Becomes Oversold” on September 23, 2016. Also Prnewswire.com published the news titled: “ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2016” on July 28, 2016. Benzinga.com‘s news article titled: “ResMed Boosted To Buy At Bank Of America” with publication date: September 29, 2016 was also an interesting one.
RMD Company Profile
ResMed Inc., incorporated on March 31, 1994, is a holding company. The Company, through its subsidiaries, designs, makes and markets equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. The Firm develops a range of products for sleep-disordered breathing and other respiratory disorders, including airdevices, informatics solutions, diagnostic products, mask systems, headgear and other accessories.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.